bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.18821/0234-5730-2016-61-3-122-126bloodjour-17Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESМодицикация стромального микроокружения у больных лейкозами до и после терапииAlterations of the bone marrow stromal microenvironment in adult patients with acute leukemia before and after treatmenthttps://orcid.org/0000-0001-8188-5557СавченкоВ. Г.SavchenkoV. G.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0003-1189-0283ШипуноваИ. Н.ShipunovaI. N.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0003-0215-9085БигильдеевА. Е.BigildeevA. E.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0002-7150-0403ДризеН. И.DrizeN. I.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0001-9947-2371ТуркинаА. Г.TurkinaA. G.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0001-6201-6276КузьминаЛ. А.KuzminaL. A.

125167, г. Москва

Moscow, 125167

https://orcid.org/0000-0002-5665-7074СорокинаТ. В.SorokinaT. V.

Сорокина Тамара Викторовна, врач отделения высокодозной химиотерапии гемобластозов, депрессий кроветворения и трансплантации костного мозга

125167, г. Москва

Sorokina Tamara V., MD, Doctor of the Department of HighDose Chemotherapy, Depressions of Hemopoiesis, and Bone Marrow Transplantation

Moscow, 125167

tamarasorokina0@yandex.ruhttps://orcid.org/0000-0001-6177-3566ПаровичниковаЕ. Н.ParovichnikovaE. N.

125167, г. Москва

Moscow, 125167

ФГБУ «Гематологический научный центр» Минздрава РоссииРоссияNational Research Center for HematologyRussian Federation201626022019613122126Copyright © Савченко В.Г., Шипунова И.Н., Бигильдеев А.Е., Дризе Н.И., Туркина А.Г., Кузьмина Л.А., Сорокина Т.В., Паровичникова Е.Н., 20192019Савченко В.Г., Шипунова И.Н., Бигильдеев А.Е., Дризе Н.И., Туркина А.Г., Кузьмина Л.А., Сорокина Т.В., Паровичникова Е.Н.Savchenko V.G., Shipunova I.N., Bigildeev A.E., Drize N.I., Turkina A.G., Kuzmina L.A., Sorokina T.V., Parovichnikova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/17

Цель исследования – охарактеризовать культуральные свойства мультипотентных мезенхимных стромальных клеток (ММСК) и колониеобразующих единиц фибробластов (КОЕф), полученных из костного мозга (КМ) больных острыми лейкозами и хроническим миелолейкозом в дебюте заболевания и после терапевтического воздействия.

Материал и методы

Материал и методы. ММСК были получены из КМ 74 больных гемобластозами. Оценивали показатели времени до нулевого пассажа, кумулятивной клеточной продукции ММСК, а также концентрации КОЕф, полученных из КМ больных гемобластозами.

Результаты

Результаты. У больных острыми лейкозами показатель времени до нулевого пассажа статистически значимо повышен в дебюте заболевания, тогда как у больных ХМЛ он сохраняется повышенным и после 3 мес терапии. Показатель суммарной клеточной продукции статистически значимо снижен в группе больных острым миелоидным лейкозом (ОМЛ) в дебюте заболевания. Концентрация КОЕф была статистически значимо снижена в обследованных группах больных в момент диагностики заболевания.

Aim of the study

Aim of the study. To investigate two types of the bone marrow (BM) stromal precursor cells, mesenchymal stromal cells (MMSCs) and fibroblast colony-forming units (CFU-Fs), in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) before and after chemotherapy.

Material and methods

Material and methods. BM derived MMSCs and CFU-Fs withdrawn from 74 AML, ALL and CML patients before and after chemotherapy were studied.

Results

Results. Concentration and culture characteristics of both types of precursors were shown to be altered in patients with acute leukemia and CML.

мультипотентные мезенхимные стромальные клеткиострый миелоидный лейкозострый лимфобластный лейкозхронический миелолейкозколониеобразующие единицы фибробластовmultipotent mesenchymal stromal cellsacute myeloid leukemiaacute lymphoblastic leukemiachronic myeloid leukemiafibroblast colony-forming unitsРФФИ, грант 12-04-00457Russian Foundation of Basic Research, No 12-04-00457ReferencesCalvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960): 841–6.Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960): 841–6.Nilsson S.K., Johnston H.M., Coverdale J.A. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001; 97(8): 2293–9.Nilsson S.K., Johnston H.M., Coverdale J.A. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001; 97(8): 2293–9.Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008; 132(4): 598–611.Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008; 132(4): 598–611.Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009; 114(6): 1150–7.Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009; 114(6): 1150–7.Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131(2): 324–36.Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131(2): 324–36.Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970; 3(4): 393–403.Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970; 3(4): 393–403.Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411): 143–7.Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411): 143–7.Frenette P.S., Pinho S., Lucas D., Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 2013; 31: 285–316. doi: 10.1146/annurev-immunol-032712-095919.Frenette P.S., Pinho S., Lucas D., Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 2013; 31: 285–316. doi: 10.1146/annurev-immunol-032712-095919.Méndez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., MacArthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308): 829–34.Méndez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., MacArthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308): 829–34.Friedenstein A.J. Precursor cells of mechanocytes. Int. Rev. Cytol. 1976; 47: 327–59.Friedenstein A.J. Precursor cells of mechanocytes. Int. Rev. Cytol. 1976; 47: 327–59.Castro-Malaspina H., Gay R.E., Resnick G., Kapoor N., Meyers P., Chiarieri D., et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980; 56(2): 289–301.Castro-Malaspina H., Gay R.E., Resnick G., Kapoor N., Meyers P., Chiarieri D., et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980; 56(2): 289–301.Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 2011; 29(5): 591–9.Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J. Clin. Oncol. 2011; 29(5): 591–9.Boyerinas B., Zafrir M., Yesilkanal A.E., Price T.T., Hyjek E.M., Sipkins D.A. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood. 2013; 121(24): 4821–31.Boyerinas B., Zafrir M., Yesilkanal A.E., Price T.T., Hyjek E.M., Sipkins D.A. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood. 2013; 121(24): 4821–31.Ben-Batalla I., Schultze A., Wroblewski M., Erdmann R., Heuser M., Waizenegger J.S., et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013; 122(14): 2443–52.Ben-Batalla I., Schultze A., Wroblewski M., Erdmann R., Heuser M., Waizenegger J.S., et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013; 122(14): 2443–52.Battula V.L., Chen Y., Cabreira Mda G., Ruvolo V., Wang Z., Ma W., et al. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013;122(3): 357–66. doi: 10.1182/blood-2012-06-437988.Battula V.L., Chen Y., Cabreira Mda G., Ruvolo V., Wang Z., Ma W., et al. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 2013;122(3): 357–66. doi: 10.1182/blood-2012-06-437988.Ito S., Barrett A.J., Dutra A., Pak E., Miner S., Keyvanfar K., et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res.2015; 14(1): 95–104. doi: 10.1016/j.scr.2014.11.007.Ito S., Barrett A.J., Dutra A., Pak E., Miner S., Keyvanfar K., et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res.2015; 14(1): 95–104. doi: 10.1016/j.scr.2014.11.007.Chandran P., Le Y., Li Y., Sabloff M., Mehic J., Rosu-Myles M., Allan D.S. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk. Res. 2015; 39(4): 486–93. doi: 10.1016/j.leukres.2015.01.013.Chandran P., Le Y., Li Y., Sabloff M., Mehic J., Rosu-Myles M., Allan D.S. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk. Res. 2015; 39(4): 486–93. doi: 10.1016/j.leukres.2015.01.013.Geyh S., Rodriguez-Paredes M., Jager P., Khandanpour C., Cadeddu R.P., Gutekunst J., et al. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia. 2016; 30(3): 683–91. doi: 10.1038/leu.2015.325.Geyh S., Rodriguez-Paredes M., Jager P., Khandanpour C., Cadeddu R.P., Gutekunst J., et al. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia. 2016; 30(3): 683–91. doi: 10.1038/leu.2015.325.Prata Kde L., Orellana M.D., De Santis G.C., Kashima S., Fontes A.M., Carrara Rde C., et al. Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp. Hematol. 2010; 38(4): 292–300.e4. doi: 10.1016/j.exphem.2010.01.006.Prata Kde L., Orellana M.D., De Santis G.C., Kashima S., Fontes A.M., Carrara Rde C., et al. Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp. Hematol. 2010; 38(4): 292–300.e4. doi: 10.1016/j.exphem.2010.01.006.Nifontova I., Svinareva D., Petrova T., Drize N. Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases. Acta Haematol. 2008; 119(2): 98–103.Nifontova I., Svinareva D., Petrova T., Drize N. Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases. Acta Haematol. 2008; 119(2): 98–103.Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009; 114(20): 4441–50.Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009; 114(20): 4441–50.Nagao T., Hugo C.M. Characteristics and functions of fibroblast colony forming cells in human bone marrow. Rinsho Ketsueki. Japanese J. Clin. Hematol. 1983; 24(11): 1455–63.Nagao T., Hugo C.M. Characteristics and functions of fibroblast colony forming cells in human bone marrow. Rinsho Ketsueki. Japanese J. Clin. Hematol. 1983; 24(11): 1455–63.Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–405. doi: 10.1182/blood-2016-03-643544.Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–405. doi: 10.1182/blood-2016-03-643544.

The authors declare that there are no conflicts of interest present.